NEWHealthcare

CVS (CVS) Restores Coverage of Zepbound, Adds Eli Lilly's Foundayo

Published on 5/28/2026

#CVS#LLY#pharmacy#weightloss#healthcare
CVS (CVS) Restores Coverage of Zepbound, Adds Eli Lilly's Foundayo

AI Summary

CVS Health (CVS) announced the restoration of coverage for Eli Lilly's (LLY) Zepbound effective October 1 and will add the Foundayo obesity pill on June 1. This adjustment positions Lilly to compete equally with Novo Nordisk in the weight loss market, affecting an estimated 25 million to 30 million Americans. CVS aims for a 10% to 15% increase in savings across weight management treatments with the updated formulary. The decision follows a prior agreement with Novo Nordisk that made Wegovy the favored choice on CVS plans while previously excluding Zepbound.

Source: Read original article (opens in new tab)

Related News

IHE vs IXJ: 39.7% vs 10% 1-Year Returns in ETFs Comparison
Markets

IHE vs IXJ: 39.7% vs 10% 1-Year Returns in ETFs Comparison

May 27

Eli Lilly (LLY) plans nearly $4 billion vaccine acquisitions
M&A

Eli Lilly (LLY) plans nearly $4 billion vaccine acquisitions

May 26

Eli Lilly (LLY) Stock Rating Reiterated Amid Gene Therapy Progress
Earnings

Eli Lilly (LLY) Stock Rating Reiterated Amid Gene Therapy Progress

May 26

Jardine Matheson (J36) Acquires I-MED for $2.4 Billion
M&A

Jardine Matheson (J36) Acquires I-MED for $2.4 Billion

May 25